HOME >> BIOLOGY >> NEWS
Case Western Reserve University licenses methoxyamine to Tracon

CLEVELAND--Case Western Reserve University's Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a "first in class" drug that targets a specific DNA repair pathway.

TRACON Pharmaceuticals is an emerging biotechnology company focused on identifying, developing and commercializing targeted therapies for cancer and angiogenesis. TRACON's management team couples their ability to execute with their extensive knowledge of oncology drug development and first generation targeted therapies, enabling them to advance the development of next generation cancer therapies.

Methoxyamine was developed by University Hospitals Case Medical Center researchers Stanton Gerson, M.D., director of the National Cancer Institute-designated Case Comprehensive Cancer Center and University Hospitals Ireland Cancer Center, and Lili Lui, Ph.D., assistant professor of medicine in the department of hematology and oncology at the Case School of Medicine. They were the first to show the therapeutic potential of Methoxyamine as an anti-cancer drug in combination with other agents.

"We are very excited about the potential of this new drug. The promise of overcoming a major mechanism of drug resistance in cancer is terrific news for many patients. We see potential applications in patients with brain cancers, melanoma, lung cancer and leukemias and perhaps other cancers," said Gerson.

Under the licensing agreement, TRACON will develop and manage clinical trials of Methoxyamine. "We are excited to be able to develop Methoxyamine. Chemotherapy represents the most commonly used class of agents to treat cancer patients. Unfortunately, resistance of cancer cells to chemotherapy prevents many patients from benefiting. Methoxyamine's unique ability to reverse res
'"/>

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
13-Oct-2006


Page: 1 2

Related biology news :

1. Study finds Western-style meat-sweet diet increases risk of breast cancer in postmenopausal women
2. Case Western Reserve University School of Medicine researchers awarded $27M for TB research
3. Case Western researcher, international team call for better global warming forecasting
4. WHSRN awarded major grant to foster shorebird conservation throughout the Western Hemisphere
5. Case Western Reserve University biologists suspect lightning fires help preserve oak forests
6. Case Western Reserve University chemist takes on HIV-1 virus with $1M support from NIH
7. Case Western Reserve University paleontologist discovers South American mammal fossils
8. Case Western Reserve University researchers find protein associated with brain cell death
9. In Western bluebird as well as human families, accumulated wealth encourages stability
10. Case Western Reserve University School of Medicine gets $4 million to make smart nanoparticles
11. ASU students host first annual Western Regional Bioethics Conference

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Case Western Reserve University licenses methoxyamine Tracon

(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: